Roche (OTCMKTS:RHHBY) Upgraded by Argus to “Buy” Rating

Argus upgraded shares of Roche (OTCMKTS:RHHBY) from a hold rating to a buy rating in a research note issued to investors on Monday, Marketbeat reports.

Several other equities analysts also recently weighed in on RHHBY. Barclays upgraded Roche from an “equal weight” rating to an “overweight” rating in a research report on Tuesday, January 6th. Citigroup assumed coverage on Roche in a research report on Tuesday, January 27th. They set a “buy” rating on the stock. HSBC reiterated a “buy” rating and set a $57.00 target price on shares of Roche in a research report on Wednesday, December 10th. TD Cowen reiterated a “hold” rating on shares of Roche in a research report on Tuesday, February 10th. Finally, Morgan Stanley reiterated an “underweight” rating on shares of Roche in a research report on Wednesday, February 4th. Five research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $57.00.

Roche Price Performance

OTCMKTS RHHBY opened at $49.98 on Monday. The company has a current ratio of 1.38, a quick ratio of 1.12 and a debt-to-equity ratio of 0.72. The business’s fifty day moving average is $54.60 and its 200 day moving average is $49.98. Roche has a fifty-two week low of $34.75 and a fifty-two week high of $60.85.

Hedge Funds Weigh In On Roche

Several large investors have recently made changes to their positions in the business. Oakworth Capital Inc. lifted its position in shares of Roche by 20.8% in the fourth quarter. Oakworth Capital Inc. now owns 1,658 shares of the company’s stock valued at $86,000 after acquiring an additional 285 shares in the last quarter. Diversified Trust Co increased its holdings in shares of Roche by 0.5% in the third quarter. Diversified Trust Co now owns 57,881 shares of the company’s stock worth $2,363,000 after purchasing an additional 310 shares during the last quarter. Canopy Partners LLC increased its holdings in shares of Roche by 4.9% in the third quarter. Canopy Partners LLC now owns 7,580 shares of the company’s stock worth $317,000 after purchasing an additional 352 shares during the last quarter. Fulton Bank N.A. increased its holdings in shares of Roche by 4.6% in the fourth quarter. Fulton Bank N.A. now owns 11,659 shares of the company’s stock worth $604,000 after purchasing an additional 508 shares during the last quarter. Finally, Curio Wealth LLC bought a new stake in shares of Roche in the third quarter worth about $25,000.

About Roche

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.